The European Medicines Agency is working with representatives of EU health technology assessment (HTA) bodies and payers to identify situations where the use of real-world evidence (RWE) might be of interest to all three of them to support their respective decision-making functions.
EMA, HTA Bodies & Payers Explore Common Ground On Use Of RWE
A technical workshop is planned for later this year to identify common “use cases” for real-world evidence that are important to the European Medicines Agency, health technology assessment bodies and payers.
